Emergent BioSolutions Inc. (NYSE:EBS) Short Interest Update

Emergent BioSolutions Inc. (NYSE:EBS) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 7,790,000 shares, a decline of 5.3% from the September 30th total of 8,230,000 shares. Based on an average trading volume of 2,780,000 shares, the days-to-cover ratio is currently 2.8 days. Currently, 15.0% of the shares of the company are short sold.

Analyst Ratings Changes

A number of research firms have weighed in on EBS. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark reiterated a “buy” rating and issued a $8.00 target price on shares of Emergent BioSolutions in a research note on Friday, August 16th.

Emergent BioSolutions Stock Performance

Shares of EBS stock opened at $9.13 on Friday. The stock has a market capitalization of $483.07 million, a P/E ratio of -0.81 and a beta of 1.59. The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16. The firm’s 50 day moving average is $8.34 and its 200 day moving average is $7.41. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). The business had revenue of $254.70 million for the quarter, compared to analysts’ expectations of $199.47 million. Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. During the same quarter in the previous year, the company posted ($1.06) earnings per share. On average, sell-side analysts anticipate that Emergent BioSolutions will post -1.3 earnings per share for the current year.

Institutional Trading of Emergent BioSolutions

Institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC lifted its stake in Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Emergent BioSolutions in the 2nd quarter worth approximately $41,000. Verus Capital Partners LLC purchased a new stake in Emergent BioSolutions in the 2nd quarter worth approximately $68,000. Avidian Wealth Solutions LLC purchased a new stake in Emergent BioSolutions in the 1st quarter worth approximately $33,000. Finally, Tidal Investments LLC purchased a new stake in Emergent BioSolutions in the 1st quarter worth approximately $34,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.